Press Releases

Date Title and Summary
Mar 15, 2023

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Achieved Record 2022 Total Net Revenues of $214 Million , a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million , a 59% YoY Increase Newly Acquired FYCOMPA® Product Expected to be Accretive to EBITDA and EPS in 2023 Reaffirming Forecast of 2023 Total Net Product
Mar 08, 2023

Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies

CORAL GABLES, Fla. , March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare
Mar 01, 2023

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023

The Company Will Host a Conference Call and Webcast on March 16, 2023, at 8:30 AM ET CORAL GABLES, Fla. , March 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Feb 22, 2023

Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day

Spotlight On Raising Awareness for Rare Diseases on February 28, 2023 Celebrating the Tireless Contributions of Patients and Advocates who Work with the Biotech Industry to Bring New Treatments to the Community CORAL GABLES, Fla. , Feb. 22, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.
Feb 07, 2023

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance

2022 Total Revenues Estimated at $214 Million, Representing 52% YoY Growth Forecast 2023 Total Revenues of Between $375 Million and $385 Million Including FYCOMPA ® , Representing YoY Growth of 75% - 80% 2023 FIRDAPSE ® Net Revenues Estimated at $245 Million to $255 Million 2023 FYCOMPA Net
Jan 25, 2023

Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII

Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience Expected to be Accretive in 2023 CORAL GABLES, Fla. , Jan. 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.
Jan 23, 2023

Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra

Announced Earlier Today -Notice Received from ANDA Filer for FIRDAPSE® CORAL GABLES, Fla. , Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.  ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel
Jan 23, 2023

Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®

CORAL GABLES, Fla. , Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it